Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics

Entrada Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $20.00 price target.

Ram Selvaraju has given his Buy rating due to a combination of factors tied to Entrada Therapeutics’ advancing clinical pipeline and anticipated data catalysts. He highlights that the company is progressing four exon-skipping DMD candidates toward and through Phase 1/2 studies across the U.S., U.K. and EU, with multiple dose-escalation cohorts and an expansion cohort designed to underpin a potential accelerated approval pathway, which together create several near- and mid-term value inflection points.

He also emphasizes that the DM1 collaboration program, now in the GALILEO Phase 1/2 MAD trial, is materially undervalued given its strategic importance and the sizeable transaction values seen in comparable DM1 deals. In his view, Entrada’s current enterprise value does not fully reflect either the breadth of its DMD franchise or the economic potential from the partnered DM1 asset, supporting both the reaffirmed Buy rating and the 12‑month price target of $20.

In another report released on February 27, Oppenheimer also reiterated a Buy rating on the stock with a $21.00 price target.